Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation

Clinical Transplantation

Volumn 22, Issue 4, 2008, Pages 439-446

  Thilly, Nathalie ^a   Bayat, Sahar ^a   Alla, François ^a   Kessler, Michèle ^b   Briançon, Serge ^a   Frimat, Luc ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Determinants of prescription; Kidney transplantation; Prescribing patterns; Renin angiotensin system inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ADULT; AGE; ANEMIA; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; FRANCE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HAZARD RATIO; HLA MATCHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROLOGIST; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DELAYED GRAFT FUNCTION; DRUG PRESCRIPTIONS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 48249095010     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00807.x     Document Type: Article

References (30)

1. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005: 68(Suppl. 99): S57.
2. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001: 345: 861.
3. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006: 354: 131.
4. Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004: 43: 1071.
5. Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol DIal Transplant 2004: 19 (Suppl. 3): iii47.
6. Bostom AD, Brown RS Jr, Chavers BM et al. Prevention of post-transplant cardiovascular disease. Reports and recommendations of an ad hoc group. Am J Transplant 2002: 2: 491.
7. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J.Am Soc Nephrol 1993: 3: 1570.
8. S tigant CE, C ohen J, V ivera M, Z altzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000: 35: 58.
9. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: Are treatment guidelines emerging? Nephrol Dial Transplant 2002: 17: 1166.
10. O moto K, T anabe K, T okumoto T, S himmura H, I shida H, T oma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003: 76: 1170.
11. I nigo P, C ampistol JM, S aracho R et al. Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract 2003: 95: 84.
12. R uggenenti P, P erna A, G herardi G, B enini R, R emuzzi G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000: 35: 1155.
13. Amuchastegui SC, Azzolini N, Mister M et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998: 9: 1948.
14. Lutz J, Risch K, Liu S et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006: 70: 1080.
15. L in J, V aleri AM, M arkowitz GS, D'A gati VD, C ohen DJ, R adhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002: 73: 783.
16. Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004: 19: 940.
17. Philipp T, Legendre C, Geiger H et al. SECRET Obtio: Study on the evaluation of candesartan cilexetil after renal transplantation (SECRET-Study). Kidney Blood Press Res 2004: 27 (Suppl.): 331.
18. Artz MA, Hilbrands LB, Borm G, Assmann KJM, Wetzels JFM. Blockade of renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004: 19: 2852.
19. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006: 17: 889.
20. Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 2006: 17: 3257.
21. Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Hörl WH, Haas M. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Transplantation 2004: 43: 1065.
22. Heinze G, Collins S, Benedict MA et al. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006: 82: 1441.
23. Giral-Classe M, Hourmant M, Cantarovich D et al. Delayed graft function of more than six days strongly decreases long-term survival of transplant kidneys. Kidney Int 1998: 54: 972.
24. Poggio ED, Wang X, Weinstein DM et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006: 6: 100.
25. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late allograft failure. Kidney Int 2002: 62: 1848.
26. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006: 15: 603.
27. National Agency of Accreditation and Evaluation in Health care. Clinical Practice Guidelines for Treatment Strategies to Slow the Progression of Chronic Renal Failure in Adults. Paris: ANAES, 2004.
28. Tiwari A, Tseng CL, Kern EF, Maney M, Miller DR, Pogach L. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease. Am J Manag Care 2007: 13: 73.
29. Miller JA, Cherney DZ, Duncan JA et al. Gender differences in the renal response to renin-agiotensin system blockade. J Am Soc Nephrol 2006: 17: 2554.
30. Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006: 21: 1389.